Literature DB >> 19049562

The coding-synonymous polymorphism rs1045280 (Ser280Ser) in beta-arrestin 2 (ARRB2) gene is associated with tardive dyskinesia in Chinese patients with schizophrenia.

Y-J Liou1, Y-C Wang, J-Y Chen, M-L Chen, T-T Chen, Y-M Bai, C-C Lin, D-L Liao, I-C Lai.   

Abstract

BACKGROUND: Tardive dyskinesia (TD) is a severe and potentially irreversible adverse effect of long-term antipsychotic treatment. Typical antipsychotics are commonly binding to the dopamine receptor D2 (DRD2), but the occurrence of antipsychotic-induced TD is rather delayed; therefore, the development of TD may be associated with mediators or signalling complexes behind DRD2, such as beta-arrestin 2 (ARRB2), an important mediator between DRD2 and serine-threonine protein kinase (AKT) signal cascade.
METHODS: A case-control study to evaluate the association between rs1045280 (Ser280Ser) and antipsychotic-induced TD was performed amongst 381 patients (TD/non-TD = 228/153).
RESULTS: There was a significant difference in the genotype distribution between TD and non-TD groups (P = 0.025); furthermore, the allelic analysis indicated that patients with T allele had increased risk of TD occurrence (OR(T) = 1.58, 95% CI = 1.14-2.19, P = 0.007).
CONCLUSIONS: To the best of our knowledge, this is the first study reporting a positive association between the SNP rs1045280 and TD in schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19049562     DOI: 10.1111/j.1468-1331.2008.02316.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  8 in total

Review 1.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

Review 2.  Arrestin mutations: Some cause diseases, others promise cure.

Authors:  Vsevolod V Gurevich; Eugenia V Gurevich
Journal:  Prog Mol Biol Transl Sci       Date:  2018-10-24       Impact factor: 3.622

3.  DISC1 regulates synaptic vesicle transport via a lithium-sensitive pathway.

Authors:  Rafael Flores; Yuki Hirota; Brian Armstrong; Akira Sawa; Toshifumi Tomoda
Journal:  Neurosci Res       Date:  2011-06-12       Impact factor: 3.304

Review 4.  Targeting β-Arrestins in the Treatment of Psychiatric and Neurological Disorders.

Authors:  Sharonda S Harris; Nikhil M Urs
Journal:  CNS Drugs       Date:  2021-03-02       Impact factor: 5.749

Review 5.  Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia.

Authors:  Yasunori Oda; Nobuhisa Kanahara; Masaomi Iyo
Journal:  Int J Mol Sci       Date:  2015-12-17       Impact factor: 5.923

Review 6.  Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders.

Authors:  Florence Cf Chang; Victor Sc Fung
Journal:  Pharmgenomics Pers Med       Date:  2014-10-13

7.  Genetic association between G protein-coupled receptor kinase 6/β-arrestin 2 and dopamine supersensitivity psychosis in schizophrenia.

Authors:  Yasunori Oda; Nobuhisa Kanahara; Hiroshi Kimura; Hiroyuki Watanabe; Kenji Hashimoto; Masaomi Iyo
Journal:  Neuropsychiatr Dis Treat       Date:  2015-07-29       Impact factor: 2.570

8.  Gray matter abnormalities in schizophrenia patients with tardive dyskinesia: a magnetic resonance imaging voxel-based morphometry study.

Authors:  Cheng-Ta Li; Kun-Hsien Chou; Tung-Ping Su; Chu-Chung Huang; Mu-Hong Chen; Ya-Mei Bai; Ching-Po Lin
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.